Novartis to acquire Excellergy in deal worth up to $2bn
Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases
Read More
Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases
Read MoreThe oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study
Read MorePH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide
Read MoreMultiple Ventyx drugs are currently in phase 2 development for inflammatory disease
Read MoreUS tariffs on UK-produced pharmaceuticals will remain at zero for three years
Read MoreThe Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer
Read MoreAcquisition will add in-house continuous manufacturing expertise and expand Sandoz’s biosimilar production capacity
Read MoreGrowth driven by increased sales in diabetes and obesity markets
Read MoreThe acquisition will expand Novartis’ neuroscience pipeline
Read MoreThe deal includes a PDE3/4 inhibitor in clinical development for COPD
Read MoreThe newly formed company has in-licensed five investigational immunology drugs from BMS
Read MoreA new restructuring programme has been approved to support the initiative
Read More
